You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2025

Servier Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Servier
International Patents:243
US Patents:14
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Servier

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Servier TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes 11,667,673 ⤷  Try for Free ⤷  Try for Free
Servier VORANIGO vorasidenib TABLET;ORAL 218784-001 Aug 6, 2024 RX Yes No 10,172,864 ⤷  Try for Free Y Y ⤷  Try for Free
Servier VORANIGO vorasidenib TABLET;ORAL 218784-001 Aug 6, 2024 RX Yes No 9,579,324 ⤷  Try for Free Y ⤷  Try for Free
Servier VORANIGO vorasidenib TABLET;ORAL 218784-001 Aug 6, 2024 RX Yes No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Servier Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2804851 CR 2023 00025 Denmark ⤷  Try for Free PRODUCT NAME: IVOSIDENIB ELLER ET FARMACEUTISK ACCEPTABELT SALT, TAUTOMER, ISOTOPOLOG ELLER HYDRAT DERAF; REG. NO/DATE: EU/1/23/1728 20230508
2804851 PA2023529 Lithuania ⤷  Try for Free PRODUCT NAME: IVOSIDENIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, TAUTOMERAS, IZOTOPOLOGAS ARBA HIDRATAS; REGISTRATION NO/DATE: EU/1/23/1728 20230504
2804851 C202330033 Spain ⤷  Try for Free PRODUCT NAME: IVOSIDENIB O UNA SAL, TAUTOMERO, ISOTOPOLOGO O HIDRATO FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1728; DATE OF AUTHORISATION: 20230504; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1728; DATE OF FIRST AUTHORISATION IN EEA: 20230504
2804851 C20230031 Finland ⤷  Try for Free PRODUCT NAME: TSEDASURIDIIN/DETSITABIIN;REG NO/DATE: EU/1/23/1756 18.09.2023
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Servier – Market Position, Strengths & Strategic Insights

Last updated: February 14, 2025

In the ever-evolving pharmaceutical industry, Servier has emerged as a significant player, carving out a unique position for itself. This French pharmaceutical company, governed by a non-profit foundation, has been making waves with its innovative approach and strategic focus. Let's dive deep into Servier's market position, strengths, and strategic insights to understand how it's shaping the competitive landscape.

Servier's Market Position

Servier has established itself as a formidable force in the pharmaceutical industry. The company's market position is characterized by several key factors:

Global Presence and Ranking

Servier has a strong global footprint, operating in over 150 countries[5]. This extensive reach has propelled the company to impressive rankings:

  • 35th largest pharmaceutical group worldwide[10]
  • 2nd largest French pharmaceutical group[10]
  • 5th leading pharmaceutical group in cardiology worldwide[10]
  • 1st leading pharmaceutical group in hypertension worldwide[10]

These rankings underscore Servier's significant market presence and its dominance in specific therapeutic areas.

Revenue and Growth

Servier's financial performance reflects its strong market position:

  • The company achieved a revenue of €5.3 billion in 2023[5]
  • Over the past five years, Servier has demonstrated a robust compound annual revenue growth rate (CAGR) of 29%[6]
  • The company projects a 15% revenue CAGR through 2028[6]

This consistent growth trajectory indicates Servier's ability to navigate market challenges and capitalize on opportunities effectively.

Servier's Core Strengths

Servier's competitive edge stems from several core strengths that set it apart in the pharmaceutical landscape:

Unique Governance Model

One of Servier's most distinctive features is its governance structure. The company is governed by a non-profit foundation, which allows it to operate with a long-term vision, free from the pressures of short-term financial targets[9]. This unique model enables Servier to:

  • Focus on patient needs and therapeutic progress
  • Invest heavily in research and development
  • Make decisions that prioritize long-term impact over immediate financial gains

Strong R&D Focus

Servier's commitment to innovation is evident in its substantial investment in research and development:

  • The company invests close to 20% of revenue from brand-name medicines in R&D each year[10]
  • Servier has 34 projects in clinical development (including 11 new molecular entities) and 23 research projects as of January 2025[10]
  • Over 60 scientific partnerships and collaborations were established in 2023/2024[10]

This robust R&D pipeline positions Servier to continue driving therapeutic progress and maintain its competitive edge.

Leadership in Cardiovascular Diseases

Servier has established itself as a leader in cardiovascular diseases, which are the leading cause of mortality worldwide:

  • The company is the 3rd largest global pharmaceutical group in cardiology and hypertension[7]
  • Servier has developed a wide range of treatments distributed in 150 countries[7]
  • The company has significantly invested in incremental innovation, including Single Pill Combinations (SPCs)[7]

This leadership in a critical therapeutic area provides Servier with a strong foundation for continued growth and impact.

Strategic Focus Areas

Servier's competitive strategy revolves around three key therapeutic areas and strategic initiatives:

1. Oncology

Servier has set its sights on becoming a focused and innovative player in oncology:

  • The company allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology[5]
  • Servier is particularly focused on hard-to-treat cancers[5]
  • The company has more than doubled the size of its oncology portfolio through strategic partnerships[6]

2. Cardiometabolism and Venous Diseases

Building on its strong foundation in cardiovascular diseases, Servier aims to:

  • Achieve revenue greater than or equal to €3 billion in this area by 2030[7]
  • Continue developing incremental innovations like Single Pill Combinations[7]
  • Expand its digital services to improve diagnosis, knowledge of chronic diseases, and therapeutic compliance[7]

3. Neuroscience and Immuno-inflammatory Diseases

Servier has identified neuroscience and immuno-inflammatory diseases as future growth drivers:

  • The company is focusing on a limited number of diseases in these areas[5]
  • Servier is employing accurate patient profiling to offer targeted therapeutic responses through precision medicine[5]

Generic Business Growth

Servier is also committed to growing its generic business:

  • The company aims to facilitate access to treatments for a larger number of patients through its generic business[7]
  • Servier has set a targeted revenue of €1.8 billion for its generic business by 2030[7]
  • The company relies on national champions and plans to seize market opportunities offered by patent exclusivity losses and biosimilar development[7]

Competitive Advantages

Servier's competitive advantages stem from its unique approach and strategic focus:

Patient-Centric Approach

Servier places a strong emphasis on patient needs:

  • The company includes the patient voice at each stage of the life cycle of a medicine[5]
  • Servier collaborated with 140 international patient organizations in 2023/2024[10]
  • This patient-centric approach helps Servier develop treatments that truly address unmet medical needs

Vertical Integration

Servier maintains control over its supply chain:

  • 95.8% of the active ingredients used in the Group's brand-name medicines are produced by Servier in France[10]
  • This vertical integration ensures quality control and reduces dependency on external suppliers

Global Footprint with Local Expertise

Servier combines global reach with local knowledge:

  • The company operates in over 150 countries[5]
  • Servier relies on strong brands in specific regions for its generic business, including France, Eastern Europe, Brazil, and Nigeria[5]
"Founded to serve health, Servier is a global group governed by a non-profit Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world."[5]

This unique positioning allows Servier to adapt to local market needs while leveraging its global resources and expertise.

Challenges and Threats

Despite its strengths, Servier faces several challenges in the competitive pharmaceutical landscape:

Intense Competition

The pharmaceutical industry is highly competitive, with major players like Pfizer, Johnson & Johnson, Merck, and Roche dominating the market[4]. Servier must continually innovate and differentiate itself to maintain its market position.

Regulatory Hurdles

Like all pharmaceutical companies, Servier faces stringent regulatory requirements that can impact product development timelines and costs[4].

Market Access and Pricing Pressures

Increasing pressure on healthcare budgets globally can affect pricing and reimbursement for pharmaceutical products, potentially impacting Servier's revenue growth.

Future Outlook and Strategic Directions

Looking ahead, Servier's future strategies focus on:

Continued Innovation

Servier plans to maintain its strong focus on R&D, particularly in oncology and neuroscience, to drive future growth.

Digital Transformation

The company is investing in digital services and technologies to enhance patient care and improve operational efficiency.

Sustainable Growth

Servier aims to balance its commitment to patient care with sustainable business practices, as outlined in its Corporate Sustainability Report[9].

Strategic Partnerships

The company will continue to seek partnerships to expand its portfolio and accelerate the development of new treatments[6].

Key Takeaways

  • Servier is a unique player in the pharmaceutical industry, governed by a non-profit foundation that allows for long-term focus on patient needs.
  • The company has established strong leadership in cardiovascular diseases and is making significant strides in oncology.
  • Servier's competitive advantages include its patient-centric approach, vertical integration, and global footprint with local expertise.
  • The company faces challenges from intense competition and regulatory hurdles but is well-positioned for future growth through continued innovation and strategic partnerships.
  • Servier's future strategies focus on innovation, digital transformation, sustainable growth, and strategic collaborations.

FAQs

  1. What makes Servier unique in the pharmaceutical industry? Servier is governed by a non-profit foundation, allowing it to focus on long-term patient needs rather than short-term financial targets. This unique governance model sets it apart from many other pharmaceutical companies.

  2. In which therapeutic areas does Servier specialize? Servier focuses on three main therapeutic areas: oncology, cardiometabolism & venous diseases, and neurology. The company is particularly strong in cardiovascular diseases and is making significant investments in oncology.

  3. How does Servier's R&D investment compare to industry standards? Servier invests close to 20% of revenue from brand-name medicines in R&D each year, which is higher than the industry average. This substantial investment underscores the company's commitment to innovation.

  4. What is Servier's approach to generic medicines? Servier has a strong generic business, aiming to facilitate access to treatments for a larger number of patients. The company targets revenue of €1.8 billion from its generic business by 2030.

  5. How is Servier addressing the challenges of the competitive pharmaceutical landscape? Servier is focusing on continued innovation, digital transformation, sustainable growth, and strategic partnerships to maintain its competitive edge and address industry challenges.

Sources cited: [1] https://www.servier-cdmo.com/about/history/ [2] https://servier.com/en/newsroom/servier-buoyed-high-performance-rd-achieve-its-ambition/ [3] https://www.servier-cdmo.com/about/ [4] https://pitchgrade.com/companies/the-medicines [5] https://servier-me.com/en/our-group/ [6] https://servier.us/our-business/ [7] https://servier.com/en/newsroom/servier-unveils-its-2030-ambition-and-revealsa-new-visual-identity/ [9] https://servier.us/about-us/ [10] https://servier.com/en/servier-group/servier-key-figures/

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.